SCOPUS 정보 검색 플랫폼

Toxicologic Pathology

Volumn 37, Issue 6, 2009, Pages 705-707

Guest editorial: The role of the toxicologic pathologist in risk management

(2) Ochoa, Ricardo a Rousseaux, Colin b

a STP (Switzerland)

b Former president STP (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOMATERIAL; MONOCLONAL ANTIBODY CD28;

DECISION MAKING; DOSE CALCULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG NOMENCLATURE; DRUG SENSITIVITY; EDITORIAL; ERROR; HAZARD ASSESSMENT; HEALTH HAZARD; HISTIOCYTOSIS; IMMUNE RESPONSE; LESIONS AND DEFECTS; OCCUPATIONAL TOXICOLOGY; PATHOLOGIST; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK MANAGEMENT; SPECIES DIFFERENCE; THERAPY EFFECT; TOXICITY TESTING; TOXICOLOGY; DRUG TOXICITY; HUMAN; PATHOLOGY;

DRUG DOSAGE CALCULATIONS; DRUG TOXICITY; HUMANS; PATHOLOGY; RISK MANAGEMENT; TOXICOLOGY;

EID: 70649098985 PISSN: 01926233 EISSN: 15331601 Source Type: Journal
DOI: 10.1177/0192623309344434 Document Type: Editorial

Times cited : (3)

References (7)

1
- 34548038122
- Should we tolerate tolerability as an objective in early drug development?
- Cohen, A. (2007). Should we tolerate tolerability as an objective in early drug development? Br J Clin Pharmacol 64, 249-52.
- (2007) Br. J. Clin. Pharmacol , vol.64 , pp. 249-52
- Cohen, A.¹

2
- 61349126783
- European Medicines Agency EMEA
- European Medicines Agency (EMEA). (2007). Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. (http://www.emea.europa.eu/pdfs/human/swp/ 2836707enfin. pdf).
- (2007) Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products

3
- 33645504676
- Learning from the tgn1412 trial
- Goodyear, M. (2006). Learning from the TGN1412 trial. Br Med J 332, 677-8.
- (2006) Br. Med. J. , vol.332 , pp. 677-8
- Goodyear, M.¹

4
- 67049107952
- The tegenero incident and the duff report conclusions: A series of unfortunate events or an avoidable event?
- Horvath, C. J., Milton, M. N., (2009). The TeGenero incident and the Duff Report conclusions: A series of unfortunate events or an avoidable event? Toxicol Pathol 37, 372-83.
- (2009) Toxicol Pathol. , vol.37 , pp. 372-83
- Horvath, C.J.¹ Milton, M.N.²

5
- 0036189753
- Recognition of adverse and nonadverse effects in toxicity studies
- Lewis, R. W. (2002). Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 30, 66-74.
- (2002) Toxicol Pathol. , vol.30 , pp. 66-74
- Lewis, R.W.¹

6
- 33744913124
- Superagonistic anti-cd28 antibody tgn1412 as a potential immunotherapeutic for the treatment of b cell chronic lymphocytic leukemia
- Abstract
- Lin C. H., Kerkau, T., Guntermann, C., Martin Trischler, M., Beyersdorf, N., Scheuring Y., Tony, H.-P., Kneitz, C., Wilhelm, M., Mueller, P., Huenig, T., and Hanke, T. (2004). Superagonistic anti-CD28 antibody TGN1412 as a potential immunotherapeutic for the treatment of B cell chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 104, Abstract 2519.
- (2004) Blood (ASH Annual Meeting Abstracts) , vol.104 , pp. 2519
- Lin, C.H.¹ Kerkau, T.² Guntermann, C.³ Trischler, M.M.⁴ Beyersdorf, N.⁵ Scheuring, Y.⁶ Tony, H.-P.⁷ Kneitz, C.⁸ Wilhelm, M.⁹ Mueller, P.¹⁰ Huenig, T.¹¹ Hanke, T.¹²

7
- 67049107949
- The emea guideline on first-in-human clinical trials and its impact on pharmaceutical development
- Milton, M. N., Horvath, C. J. (2009). The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development. Toxicol Pathol 37, 363-71.
- (2009) Toxicol Pathol. , vol.37 , pp. 363-71
- Milton, M.N.¹ Horvath, C.J.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.